Cargando…

Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data

Replication-competent (oncolytic) viruses (OV) as cancer immunotherapeutics have gained an increasing level of attention over the last few years while the clinical evidence of virus-mediated antitumor immune responses is still anecdotal. Multiple clinical studies are currently ongoing and more immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamarin, Dmitriy, Pesonen, Sari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968310/
https://www.ncbi.nlm.nih.gov/pubmed/26176173
http://dx.doi.org/10.1089/hum.2015.055
_version_ 1782445639500562432
author Zamarin, Dmitriy
Pesonen, Sari
author_facet Zamarin, Dmitriy
Pesonen, Sari
author_sort Zamarin, Dmitriy
collection PubMed
description Replication-competent (oncolytic) viruses (OV) as cancer immunotherapeutics have gained an increasing level of attention over the last few years while the clinical evidence of virus-mediated antitumor immune responses is still anecdotal. Multiple clinical studies are currently ongoing and more immunomonitoring results are expected within the next five years. All viruses can be recognized by the immune system and are therefore potential candidates for immune therapeutics. However, each virus activates innate immune system by using different combination of recognition receptors/pathways which leads to qualitatively different adaptive immune responses. This review summarizes immunological findings in cancer patients following treatment with replication-competent viruses.
format Online
Article
Text
id pubmed-4968310
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-49683102016-08-09 Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data Zamarin, Dmitriy Pesonen, Sari Hum Gene Ther Reviews Replication-competent (oncolytic) viruses (OV) as cancer immunotherapeutics have gained an increasing level of attention over the last few years while the clinical evidence of virus-mediated antitumor immune responses is still anecdotal. Multiple clinical studies are currently ongoing and more immunomonitoring results are expected within the next five years. All viruses can be recognized by the immune system and are therefore potential candidates for immune therapeutics. However, each virus activates innate immune system by using different combination of recognition receptors/pathways which leads to qualitatively different adaptive immune responses. This review summarizes immunological findings in cancer patients following treatment with replication-competent viruses. Mary Ann Liebert, Inc. 2015-08-01 2015-07-14 /pmc/articles/PMC4968310/ /pubmed/26176173 http://dx.doi.org/10.1089/hum.2015.055 Text en © Dmitriy Zamarin and Sari Pesonen 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Reviews
Zamarin, Dmitriy
Pesonen, Sari
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
title Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
title_full Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
title_fullStr Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
title_full_unstemmed Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
title_short Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data
title_sort replication-competent viruses as cancer immunotherapeutics: emerging clinical data
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968310/
https://www.ncbi.nlm.nih.gov/pubmed/26176173
http://dx.doi.org/10.1089/hum.2015.055
work_keys_str_mv AT zamarindmitriy replicationcompetentvirusesascancerimmunotherapeuticsemergingclinicaldata
AT pesonensari replicationcompetentvirusesascancerimmunotherapeuticsemergingclinicaldata